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Background: Idiopathic pulmonary fibrosis (IPF) is a fibroproliferative disorder.
Cytokines contribute an important but yet undefined role to its pathogenesis.
Objectives: The present study aims to compare serum levels of cytokines involved in
Th-1 and Th-2 immunity, such as interleukins (IL) IL-2, IL-4, IL-8, IL-10, interferon-g
(IFN-g) and IL-12 (p40) in patients with IPF and healthy volunteers. Twenty patients
with IPF and 40 healthy controls (HC) participated.
Methods: Cytokines were assessed by enzyme-linked immunoabsorbent assay
(ELISA).
Results: Median values of serum IL-2, IL-8, IL-10, IL-12 (p40) were higher in the IPF
than the control group: IPF group: 1.05U/ml, 12.55, 10.13, 44.17 pg/ml; control
group: 0.05U/ml, 6.91, 0.75, 4.51 pg/ml, respectively ðPo0:05Þ. IFN-g serum levels
were lower in the IPF (0.19 pg/ml) than in the control group (0.49 pg/ml). IL-4 values
did not differ in a statistically significant way among the groups: 8.40 pg/ml in the
IPF group, and 7.46 pg/ml in the control group ðP40:05Þ. IL-4 positively correlated to
fast expiratory volume in 1 s (FEV1%) and forced vital capacity (FVC%), while IL-8
negatively correlated to the respective values ðPo0:005Þ.
Conclusions: IL-2, IL-8, IL-10 and IL-12 (p40) were found to be elevated in the sera
of patients with IPF. IFN-g was found to be decreased in the sera of patients with IPF.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
3218316; fax: +30 210 3218316.
il.com (P.G. Tsoutsou).
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Idiopathic pulmonary fibrosis (IPF) is a chronic
fibroproliferative disorder, which consists of the
progressive fibrosis of the interstitial spaces of the
lung with subsequent loss of the normal parench-
ymal architecture.1 Cytokines are important in the
pathogenesis of IPF.2 Cytokines participate in the
Th-1 or Th-2 types of immune response, which are
different pathways of immunological reactions,
orchestrated by T-helper cells.3 It has not yet been
made definitely clear which of these two types of
response dominates in the pathogenesis of IPF, but
it is beyond any doubt that they contribute a major
role to it.4
Cytokines such as interferon-g (IFN-g) and inter-
leukin-12 (IL-12) are essential in the development
of Th-1 immune responses, while IL-4, IL-10 and the
p40 subunit of IL-12 are of major significance in Th-
2 immune responses.3 IL-8 is the major neutrophil
chemotactic factor of the lung.5 IL-2 is an im-
portant inflammatory cytokine. In that concept,
the above cytokines present an increased interest
in the understanding of the pathogenesis of IPF.
Furthermore, as suggested already by research-
ers of the present study, cytokine tissue and serum
levels could be of value in the enrollment of
patients participating in clinical trials with immu-
nomodulatory agents, such as IFN-g-1b.6 Having
been studied mainly in the bronchoalveolar lavage
fluid (BALF) and tissues of patients with interstitial
lung disease (ILD), an insufficient amount of data
exist concerning their serum levels (apart from
those of IL-8) and their clinical significance in such
patients.Table 1 Summary of the characteristics of the studied i
Mean (7
Idiopathic
Females/males 11/9
Age (years) 72 (77.2
Nonsmokers/smokers 11/9
Clubbing (yes/no) 15/5
Duration of symptoms (months) 24 (73.4
Dyspnea
Grades 1–4 (median) 3.00 (70
FEV1% 78.00 (7
FVC% 61.80 (7
FEV1%/FVC% 0.92 (70
Dlco/Va (%) 64.75 (7
PO2 (mmHg) 70.00 (7
PCO2 (mmHg) 37.80 (7The aim of this present study is therefore to
focus on the levels of the above-mentioned
cytokines, both fibrogenic and nonfibrogenic, in
the serum of patients with IPF, compared to those
of healthy controls (HC). Working with patients
with IPF being referred to the researchers’ Depart-
ment from around all Central Greece, researchers
of the present study aim to detect preliminary data
for future research concerning the clinical use of
cytokines in IPF.Materials and methods
A prospective study was conducted from 12/1999 to
8/2001 in the Pulmonary Department of the
University Hospital of Thessalia, where all
patients with ILD from Central Greece are referred.
Among those patients selected to participate in the
study were only those who fulfilled strict clinical
criteria.
Methodology: The methodology pattern was as
follows: Two groups were formed. Group 1 con-
sisted of 20 patients with IPF, who fulfilled the
clinical criteria described in the ATS/ERS consen-
sus.7 Group 2 consisted of 40 healthy volunteers of
adjusted age and sex (Table 1). Persons in both
groups did not receive any medication at the time
of the diagnosis.
Patients under treatment and those who were
suffering from other systematic diseases were
excluded. An informed consent was obtained from
all individuals that finally participated in the
present study. Data regarding patients were se-
lected following the establishment of the diagnosis,ndividuals.
SD)
pulmonary fibrosis20 Controls40
20/20
6) 67 (710.50)
23/17
No
0) —
.76) —
25.06) 90.50 (710.00)
22.56) 92.00 (77.00)
.21) 0.97 (70.7)
21.21) 81.75 (723.90)
19.13) —
4.93) —
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HRCT profile at the time of the diagnosis.
Technique: dyspnea was scored in four grades:
1 ¼ exercise dyspnea, 2 ¼ walking dyspnea, 3 ¼
common activity dyspnea and 4 ¼ resting dyspnea.
Blood samples were taken under sterile conditions,
serum was collected and then stored at 80 1C.
Hemolysed specimens were excluded and a second
sample was recollected. Two cytokine measure-
ments were performed for every sample and the
mean value of the two assessments was included in
the statistical analysis.
Interleukins
Interleukins IL-2, IL-8, IL-4, IL-10, IL-12 (p40
subunit) and IFN-g were measured by an enzyme-
linked immunoabsorbent assay (ELISA) using Bio-
source ELISA kits, according to the manufacturer’s
guidelines. ELISA is a sensitive and specific method
in the assessment of cytokine levels in the serum.8
Statistical analysis
Data are expressed as median and range. Compar-
isons between the two groups were performed
using the SPSS 8 for Windows Statistical program. A
multivariate analysis was first performed in order
to detect independent correlations between va-
lues. Important correlations were then determined
by Spearman’s correlation (nonparametrical va-
lues). Correlations at a statistical high level (P) of
less than 0.05 were regarded as statistically
significant.9,102015N= 
IPFControls
IL
-1
2
300
200
100
0
-100
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Boxplot 1 IL-12 values for patients with IPF and controls.Results
Description of the sample: The present sample
consists of patients coming from the main agricul-
tural area in Greece and among them all the
socioeconomic classes have been represented.
Smoking habits were equal between the two
groups. Patients with IPF had a long duration of
symptoms before proceeding to seek for medical
help (mean: 24 months, standard deviation (SD): 3.4
months), dyspnea of a mean grade of 3 (SD: 0.76)
and functional respiratory tests compatible with a
restrictive type of disorder (Table 1). Blood gases
were impaired in patients with IPF (Table 1). All
patients had fine crackles (‘‘Velcro’’ type) in
auscultation, and clubbing was present in 15/20
patients. All of the patients suffered from progres-
sive dyspnea on exertion. Coughing was present in
14/20 patients, dry in 10/20 and productive in 4/20. Haemoptysis was present in 2/20 patients.
Right ventricular function was not impaired at the
time of the evaluation (based on echocardiogram
(ECG) performed in all of the patients, and cardiac
ultrasound performed in 15/20 patients).
Forty healthy volunteers made their blood
samples available in that period of time. They
were aged 67 years old (SD: 10.5 years) and 20/40
were males. In them, as well, all the socioeconomic
classes were represented. At the time of the
collection of the samples they were healthy as
assessed by physical examination, chest X-ray, ECG
and spirometry. They, as well, were not receiving
any medication at the time of the sample collec-
tions.
IL-8, IL-2, IL-10 and IL-12 were elevated in the
IPF group. IFN-g was decreased in the IPF group
compared to the HC. IL-4 and IL-8 correlated to the
spirometry values, such as fast expiratory volume in
1 s (FEV1%) and forced vital capacity (FVC%). IL-4
positively correlated to these values, while IL-8 did
so inversely.
IL-10 was elevated in the IPF group (med-
ian ¼ 7.085 pg/ml, range: 25.00 pg/ml), compared
to the control group (median: 0.70 pg/ml, range:
2.59 pg/ml) ðP ¼ 0:022Þ. The mean value of IL-8 was
significantly higher in the IPF group (median: 12.00,
range: 17.42 pg/ml) than in the HC group (median:
4.50 pg/ml, range: 24.00 pg/ml) ðP ¼ 0:001Þ. IL-2
was significantly higher in the IPF group (median:
0.50 pg/ml, range: 3.00 pg/ml) than in the HC
group (median: 0.05 pg/ml, range: 0.06 pg/ml)
ðPo0:001Þ. IL-4 serum levels were equal between
the IPF group (median: 7.25, range: 22.00 pg/ml)
and the HC group (median: 7.22 pg/ml, range:
7.15 pg/ml) ðP ¼ 0:41Þ. IL-12 was significantly high-
er in the IPF group (median: 28.37 pg/ml, range:
202.38 pg/ml) than the HC group (median: 4.10 pg/
ml, range: 5.30 pg/ml) ðP ¼ 0:004Þ (Boxplot 1).
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(median: 0.08 pg/ml, range: 0.80 pg/ml) than the
volunteers’ group (median: 0.49 pg/ml, range:
0.11 pg/ml) ðPo0:001Þ (Boxplot 2, Table 2).
IL-4 positively correlated to FEV1% ðR ¼ 0:69; P ¼
0:001Þ and FVC% ðR ¼ 0:56; P ¼ 0:012Þ. IL-8 nega-
tively correlated to FEV1% ðR ¼ 0:58; P ¼ 0:008Þ
and FVC% ðR ¼ 0:47; P ¼ 0:04Þ (Scatterdiagrams 1
and 2).Discussion
Th-1 and Th-2 immune responses are crucial in the
development of lung fibrosis. Several studies
attempt to recognize the dominant type of immune
response in ILDs, among which, also in IPF.4
However, this issue has not been made yet clear.
It was long thought that Th-2 type of immunity, to
an unknown yet trigger, dominates in IPF and that a
change in that type of immune response towards
the more favorable Th-1 response, through immu-Table 2 Biochemical serum characteristics of patients w
and controls.
Median (7range)
Idiopathic pulmonary fibrosi
IL-2 (U/ml) 0.5 (73.00)
IL-8 (pg/ml) 12.00 (717.42)
IL-4 (pg/ml) 7.25 (722.00)
IL-10 (pg/ml) 6.50 (725.00)
IL-12 (pg/ml) 28.38 (7202.38)
IFN-g (pg/ml) 0.09 (70.80)
2037N= 
IPFControls
1.0
0.8
0.6
0.4
0.2
0.0
-0.2
4661
IF
N
-Y
 
Boxplot 2 Distribution of values of IFN-g in patients and
controls.nomodulators such as IFN-g-1b, would prove bene-
ficial for the clinical outcome of those patients.2
Unfortunately, neither the Th-2 dominance, nor the
therapeutic role of Th-1 response have been
completely established.
However, the presence of cytokines in the serum
of patients with IPF, participating in either of the
types of immune response, is of major interest both
in clinical as well as research terms. The present
study aims to evaluate the presence of significant
cytokines of either of the types of immune
response, in the sera of patients with IPF, in order
to trigger further research of those presenting
particular interest. The first approach to the study
of cytokines in the serum is the identification of the
major differences between their serum levels in
patients with IPF and the respective levels in the
sera of healthy volunteers.
Nevertheless, two important points must be
underlined: First, although the patients were
assessed at a ‘‘common’’ moment, that is the time
the diagnosis was established, they cannot
be expected to be in the exact same phase of theith idiopathic pulmonary fibrosis (IPF) (median7range)
P
s Controls
0.05 (70.06) o0:001
4.5 (724.00) 0:001
7.22 (77.15) 0:41
0.70 (72.59) 0:022
4.10 (75.3) 0:004
0.49 (70.11) o0:001
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Scatterdiagram 1 Correlations between IL-4 and FVC%.
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Scatterdiagram 2 Correlations between IL-8 and FVC%.
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useful means of assessing the disease in general,
not a particular phase of it.
Second, it must be strongly underlined that IPF is
an organ-specific disorder, while cytokine levels
were assessed in the serum. It is important to point
out that serum levels of a particular cytokine do
not necessarily represent the respective tissue
ones. However, if these distal levels prove to be
useful in assessing the disease, this information is
important because they are more easily evaluated
and might represent a realistic way to monitor such
patients. Herein follows a discussion of each
particular cytokine studied, as well as the impor-
tance of the results already provided.
IL-2 was increased in the patients’ sera as
compared to that of the HC. IL-2 participates in
the pathogenesis of fibrosis, as it is the first
inflammatory cytokine to be excreted in any
immune response.3 IL-2 participates in the immu-
nity of T-memory cells. Its soluble receptor is
detected in elevated values in the serum of
patients with active ILD.11 It correlates to the
amount of inflammatory lesions in the lung.12 IL-2 is
mostly used as a serum marker in sarcoidosis.13,14
However, it is not important as a specific marker for
any ILD.14 Its increased levels in the sera of patients
with IPF should therefore be considered with
caution in the clinical setting. However, it might
be a cytokine worth considering in future studies of
the pathogenesis of IPF, or in the enrollment of
patients with IPF in clinical trials.
IL-10 is specifically elevated in the sera of
patients with IPF.15,16 As mentioned already by
the researchers of the present study, serum levels
of IL-10 were not detected in the sera of patients
with pulmonary fibrosis of a secondary cause, while
being elevated in patients with IPF.15 IL-10 partici-pates in Th-2 immunity. It is generally regarded as
an anti-inflammatory IL, produced by alveolar
macrophages (AMs); in IPF the products of the gene
of IL-10 are increased in order to control the
proinflammatory action of tumor necrosis factor
alpha (TNF-a).17,18 Paradoxically, its levels in the
BALF of IPF patients have not been found to be
high.18 In the bleomycin-induced model of lung
fibrosis, both ‘‘promoter’’ cytokines such as TNF-a,
TNF-b, IFN-g and IL-2, as well as a ‘‘suppressive’’
cytokine, such as IL-10, were found to be elevated
in the fibrotic lung.19 In another study, the levels of
IL-10 in the tissues of patients with IPF were not
elevated compared to those of HC.20
To the researchers’ knowledge, its levels in the
serum of patients with IPF have not been studied
before. Given the evolving data suggesting it is
involved in the pathogenesis of IPF, and the
researchers’ failure to detect any IL-10 levels in
patients with other ILDs, it might be suggested that
further research regarding IL-10’s possible role in
the pathogenesis and treatment of patients with
IPF might be interesting. Given the failure of
patients with IPF to respond to corticosteroids,
while patients with ILD due to other causes benefit
from them, as well as the different IL-10 serum
status in those patients groups, it might be
suggested that IL-10 might be a cytokine especially
involved in IPF, and therefore of evolving signifi-
cance for future research.
However, once again, the serum levels do not
necessarily represent the tissue ones. Therefore,
the elevated levels of IL-10 in the sera of patients
with IPF might just represent the lack of effect of
IL-10 in suppressing the inflammatory response in
IPF. IL-10 might be stimulated by other cytokines,
as part of a Th-2 response and therefore might be a
less significant cytokine in IPF. Those two contra-
dictory hypotheses might be elucidated when more
data from future research are made available.
IL-8 is the most well-studied cytokine in patients
with fibrosis.5 IL-8 has been found to be elevated in
the BALF and serum of patients with IPF and to
reflect disease activity.21 It is released by activated
mononuclear macrophages and has a potent che-
motactic activity for polymorphonuclear leuko-
cytes. Therefore, it contributes to the amount of
neutrophilic alveolitis in IPF. It is elevated in the
BALF cells of patients with IPF and sarcoidosis,
though it is not clear if it corresponds with the BALF
neutrophilia or not.22,23 It seems probable that IL-8
is increased in the BALF of patients with IPF during
the subacutely progressive phase rather than the
chronic phase of the disease.24
In accordance with the available data, in the
present study IL-8 was elevated in patients with IPF
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result could be interpreted as IL-8 being a serum
marker of spirometry impairment in patients with
IPF. However, since IL-8 has been fairly studied in
IPF and, furthermore, current concepts about the
pathogenesis of IPF suggest that the role of
neutrophil inflammation and alveolitis in it is of
minor importance, IL-8 seems to be less involved in
the pathogenesis of IPF than previously thought.25
However, its clinical value should not be under-
estimated, since it is clearly a cytokine the serum
levels of which represent physiological impairment
in IPF.21
IL-4 has not been previously studied in the sera of
patients with IPF. IL-4 is a cytokine participating in
the development of the Th-2 response.4 It is a
fibrogenic cytokine, secreted by cells such as T-
lymphocytes and mast cells, that increases collagen
production by fibroblasts.26 Greater numbers of IL-4
positive cells in IPF tissues are found at the
advanced stage of the disease, and augmented
amounts of IL-4 have been reported in situations
such as radiation-induced pneumonitis in rats.27,28
IL-4 correlated positively to the spirometry values
of FEV1% and FVC%. Therefore, it correlates with a
less severe restrictive disorder. However, its serum
levels in patients with IPF are among the normal
values, as assessed by the HC group. This present
study does not suggest that serum measurements of
IL-4 are of major interest in the clinical setting of
patients with IPF.
IFN-g was decreased in the sera of patients with
IPF. IFN-g derives by T-lymphocytes and mast cells
and decreases collagen production by fibroblasts.29
It is a major cytokine of the Th-1 immune
response.3 IFN-g is considered to have an anti-
fibrotic effect based on the down-regulation of the
bleomycin-induced overexpression of transforming
growth factor-beta (TGF-b) and subsequently pro-
collagen m-RNAs, leading to a decreased collagen
content.30 The pathogenesis of fibrosis partly
depends on the imbalance between cytokines
derived by type II alveolar epithelial cells, such as
IL-4 and IFN-g with contradictory effects, which
also reflect a Th-1–Th-2 imbalance, respectively.31
IFN-g has already been found to be decreased in
the fibrotic tissue.32 It has also been shown that
patients with IPF who have high levels of IFN-g in
their serum respond better to corticosteroids.32 In
an effort to convert the Th-2 environment in the
field of fibrosis, IFN-g-1b has been tested as a
therapeutic agent in patients with IPF.33 The results
of a preliminary study showed that patients with
IPF who had reduced amounts of IFN-g in their
tissues, benefited from therapy with the above-
mentioned agent.33 However, a large randomizedmulticentered trial, in which tissue levels of IFN-g
were not assessed, proved that IFN-g-1b did not
provide any important improvement in those
patients.34 The question remains however, if IFN-
g-1b would have been beneficial for a subgroup of
patients having reduced tissue IFN-g.
It is therefore agreed that IFN-g is too important
an agent in IPF to be abandoned in future
research.35 Assessment of IFN-g serum levels in
patients with IPF of the present study proved that
they have inadequate circulating IFN-g. Further
correlations between tissue and serum levels of
IFN-g in patients with IPF are needed, in order to
selectively enroll patients in future trials with IFN-
g-1b. Clearly, future studies are needed to eluci-
date its role in this devastating disease.
IL-12 derives principally by activated macro-
phages. Little data exist about the role of IL-12 in
lung fibrosis. Existing studies are mostly made in
mice, and prove that IL-12 plays a certain role in
the pathogenesis of lung fibrosis by regulating the
T-helper type-1 cell action.36 IL-12 is comprised by
two separate subunits: p40 and p35 which form the
p70, that corresponds to IL-12.37 While p35 subunit
might have an antifibrotic effect, the p40 subunit
participates in T-helper 2-cell polarization, which
plays an important role in fibrosis due to inhaled
inorganic particles.38 IL-12 (p40 subunit) was
elevated in the sera of IPF patients of the present
study. It seems to be an interesting cytokine to
study, since the clarification of its role in the
pathogenesis of fibrosis might lead to new ther-
apeutic approaches.39 Results of the present study
suggest it is worth studying in the clinical setting,
as well.
Cytokines are considered to play a significant
role in lung injury and repair and are important in
the pathogenesis of fibrosis. Some of them seem to
participate in the local injury and inflammatory
reaction (IL-1, IL-8, TNF-alpha), while some others
are involved in tissue repair and fibrosis (PDGF, IGF-
1, TGF-b). Cytokines form complex networks,
orchestrated by key cytokines, and the most
important feature in understanding the pathogen-
esis of the fibrosis seems to be the balance of
positive (profibrogenic) and negative (antifibro-
genic) forces generating from interactions between
the various cytokines.40 In those complex networks,
cytokines regulate the fibroblast function and
fibroblasts feedback to regulate the inflammatory
function. A given IL, however, has variable effects
depending on the activation of the target cell, the
local presence of other cytokines and the ability of
the target cell to produce bioactive autocoids, such
as prostaglandins. Cytokines in combination have
different effects on fibroblast proliferation than
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the main limitations in the study of such molecules.
Cytokines involved in lung fibrosis have been
rather adequately studied in the BALF of patients
with IPF or other interstitial fibrosis, and the local
action at the place of inflammation and fibrosis is
becoming more evident. However, apart from IL-8,
there are not enough data considering the values of
the ILs in the serum of patients with IPF.
In conclusion, the present study of serum
cytokines in IPF suggests that IFN-g, participating
in Th-1 immune response was decreased in the sera
of the studied patients with IPF. IL-4, participating
in Th-2 response was within the normal values in
the sera of patients with IPF. On the other hand, IL-
2 (a purely inflammatory cytokine), IL-10 and IL-12-
p40 subunit (participating in Th-2 immunity), as
well as IL-8, which is a chemoattractant cytokine,
were all increased in the sera of the studied
patients with IPF. The Th-2 predominance, which
is considered to be one of the main, if not the
major pathogenetic factor in IPF is suggested,
though not definitely, also by results of the present
study. The present report aims to provide pre-
liminary data in order to induce future research in
the field of cytokines and IPF, either in the serum or
in the tissues of such patients. Hopefully, the
exploration of their clinical significance and possi-
ble role in the pathogenesis of IPF would lead to
new therapeutic paths.Acknowledgments
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